Revue Medicale de Liege · Nov 2026

English Title : Advances in tirzepatide : an update on new studies and pre-specified analyses

By Scheen A

Tirzepatide is a unimolecular dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In Belgium, it is marketed and reimbursed under specific conditions for the treatment of type 2 diabetes (T2D), whereas it is not reimbursed for the treatment of obesity. The main findings from the SURPASS programme in T2D and the SURMOUNT programme in obesity have previously been reported in this journal, including the SURPASS-CVOT landmark trial, which compared tirzepatide with dulaglutide in patients with T2D at high cardiovascular risk. This article presents several prespecified secondary analyses of SURPASS-CVOT published in 2026. These include an analysis comparing tirzepatide with a virtual placebo, an assessment of the effect of tirzepatide on expanded cardiovascular endpoints (MACE-4-6P), and an evaluation of its renal benefits using clinically relevant kidney-related outcomes. In addition, in the field of obesity, the article reports the results of the SURMOUNT-MAINTAIN study, a trial designed to limit weight regain following discontinuation of tirzepatide treatment. Taken together, these new data further confirm the efficacy of tirzepatide across clinically meaningful endpoints, while supporting its safety profile and favourable tolerability, consistent with previously reported findings.

The paperPubMed 43036961Interventions

AgingResearch.News